Freelite Serum Free Light Chain Assays
This site is for Healthcare Professionals only
Click here for Patient Information
Latest News Headlines
- New screening algorithm with Freelite reduces labour-intensive IFE in Australian study21 January 2010
- Wikilite.com – a new online educational resource for Freelite™ and Hevylite™14 December 2009
- Simple and efficient initial diagnostic screen for monoclonal gammopathy using Freelite09 November 2009
- First Hevylite™ assays are available02 September 2009
- First publication supporting clinical utility of Hevylite™14 August 2009
- Recent studies highlight renal applications for serum free light chain assays.03 August 2009
Freelite is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia. There is now significant clinical evidence indicating the benefit of serum free light chain assays in initial screening for monoclonal gammopathies, identifying AL amyloidosis and Nonsecretory MM patients missed by conventional electrophoretic methods, as a prognostic indicator for progression in myeloma*, for risk stratification of MGUS patients* and rapid evaluation of treatment efficacy.
Freelite assays were developed by Binding Site to measure free lambda and free kappa immunoglobulin light chains. Our expertise in the manufacture of antibodies has enabled us to provide a quantifiable, highly specific, automatable free light chain assay for serum.
Review the clinical evidence for the utility of Freelite in detecting and monitoring plasma cell disorders and compare the results from laboratory protocols with and without Freelite.
* In the USA diagnostic use of this product is restricted to those stated in the product insert
Latest News 21 January 2010
New screening algorithm with Freelite reduces labour-intensive IFE in Australian study
Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy
Richard B. Fulton and Suran L. Fernando. Ann Clin Biochem 2009;46: 407-12
The authors examined the optimal combination of laboratory tests to screen for monoclonal gammopathy. They commented: "The FLC ratio is a more sensitive method than uIFE in the detection of monoclonal light chains and may substantially reduce the need for onerous 24 h urine collections."
By changing from a strategy where specific assays were requested by clinicians to a standardised protocol which utilised SPE, serum free light chains and restricted the use of immunofixation electrophoresis (IFE), the detection of monoclonal (M)-proteins was maximised whilst significant reductions in labour costs were made.
Review a suggested Initial Screening Investigation protocol using Freelite serum free light chains or contact us to request a copy of the Fulton & Fernando publication - code MKG543
More
